Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that Company management will present at the Jefferies Virtual Healthcare Conference taking place June 1-4, 2021. The Company will also participate in one-on-one investor meetings at the conference.
Details on the presentation can be found below.
| Date: | Thursday, June 3, 2021 |
| Time: | 2:30 PM ET |
| Format: | Corporate presentation |
| Webcast: | https://wsw.com/webcast/jeff174/virx/1890351 |
A replay of the presentation will be available on the “Events and Webcasts” section of the Viracta website at https://viracta.investorroom.com/events-and-webcasts#past.
About Viracta Therapeutics, Inc.
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta’s proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.
For additional information please visit www.viracta.com.
| Investor Relations Contact: | Company Contact: |
| Joyce Allaire | Dan Chevallard |
| LifeSci Advisors | Chief Operating Officer and Chief Financial Officer |
| [email protected] | [email protected] |
| (212) 915-2569 | (858) 771-4193 |
SOURCE Viracta Therapeutics, Inc.
